Comparative Pharmacology
Head-to-head clinical analysis: JUNEL FE 1 20 versus MARLISSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JUNEL FE 1 20 versus MARLISSA.
JUNEL FE 1/20 vs MARLISSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and norethindrone suppresses gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, induces changes in cervical mucus and endometrium to impede sperm penetration and implantation.
MARLISSA is a combination of ethinyl estradiol, a synthetic estrogen, and drospirenone, a progestin with antimineralocorticoid and antiandrogenic activity. It suppresses gonadotropins, inhibiting ovulation, and alters cervical mucus and endometrial lining.
One tablet orally once daily for 21 days, followed by 7 days of placebo tablets. Each active tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol.
MARLISSA 20 mg orally once daily with or without food.
None Documented
None Documented
Ethinyl estradiol: 13-27 hours (terminal); norethindrone: 5-14 hours (terminal). Clinically, steady-state is achieved within 5-6 days.
Terminal elimination half-life is 12-18 hours (mean 15 hours) in healthy adults. In moderate-to-severe hepatic impairment, half-life may be prolonged to 30-40 hours; no significant change in renal impairment.
Renal (primarily as metabolites; ~50-60% of dose), fecal (~30-40% of dose). Unchanged drug excretion is minimal.
Primarily renal (75-80% as unchanged drug) via glomerular filtration and tubular secretion; 10-15% fecal via biliary excretion; 5-10% metabolized with metabolites also renally eliminated.
Category C
Category C
Oral Contraceptive
Oral Contraceptive